Skip to Content

Drug interactions between Mavyret and Vosevi

Results for the following 2 drugs:
Mavyret (glecaprevir/pibrentasvir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir)

Interactions between your drugs

There were no interactions found in our database between Mavyret and Vosevi. However, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Mavyret

A total of 147 drugs (751 brand and generic names) are known to interact with Mavyret.

Vosevi

A total of 178 drugs (764 brand and generic names) are known to interact with Vosevi.

Drug and food interactions

Moderate

voxilaprevir food

Applies to: Vosevi (sofosbuvir / velpatasvir / voxilaprevir)

Food may help the absorption of voxilaprevir. You should take this medication with food as directed.

Switch to professional interaction data

Moderate

glecaprevir food

Applies to: Mavyret (glecaprevir / pibrentasvir)

Food may help the absorption of glecaprevir. You should take this medication with food as directed.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Protease inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'protease inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'protease inhibitors' category:

  • glecaprevir (active ingredient in Mavyret (glecaprevir/pibrentasvir))
  • voxilaprevir (active ingredient in Vosevi (sofosbuvir/velpatasvir/voxilaprevir))

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Duplication

NS5A inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'NS5A inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'NS5A inhibitors' category:

  • pibrentasvir (active ingredient in Mavyret (glecaprevir/pibrentasvir))
  • velpatasvir (active ingredient in Vosevi (sofosbuvir/velpatasvir/voxilaprevir))

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide